Clinical Trial Update: Randomised Study to Compare the Efficacy of AZD6244 vs TMZ [Phase 2]

View source ↗

Summary

A Phase 2 randomized trial comparing AZD6244 (selumetinib) versus temozolomide in melanoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• AZD6244 (selumetinib)
• Temozolomide (Temozolomide)

Snippet

Sponsor: AstraZeneca | Conditions: Melanoma | Phase 2 | Status: COMPLETED